PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,262,984 | -36.9% | 271,016 | +0.5% | 0.00% | -50.0% |
| Q2 2023 | $3,588,314 | +37.5% | 269,798 | +19.8% | 0.00% | +33.3% |
| Q1 2023 | $2,608,893 | +47.9% | 225,293 | +4.5% | 0.00% | +50.0% |
| Q4 2022 | $1,764,002 | +33.7% | 215,648 | -5.1% | 0.00% | +100.0% |
| Q3 2022 | $1,319,000 | +32.0% | 227,272 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $999,000 | -55.4% | 226,173 | -8.2% | 0.00% | -50.0% |
| Q1 2022 | $2,241,000 | -47.6% | 246,254 | +17.8% | 0.00% | 0.0% |
| Q4 2021 | $4,277,000 | -34.2% | 209,047 | -17.8% | 0.00% | -50.0% |
| Q3 2021 | $6,499,000 | -16.2% | 254,343 | +14.8% | 0.00% | 0.0% |
| Q2 2021 | $7,751,000 | +1.8% | 221,627 | -3.0% | 0.00% | 0.0% |
| Q1 2021 | $7,612,000 | +6.5% | 228,505 | -17.1% | 0.00% | +33.3% |
| Q4 2020 | $7,150,000 | +354.3% | 275,641 | +72.8% | 0.00% | +200.0% |
| Q3 2020 | $1,574,000 | +241.4% | 159,515 | +19.5% | 0.00% | – |
| Q2 2020 | $461,000 | -85.7% | 133,540 | -87.3% | 0.00% | -100.0% |
| Q1 2020 | $3,224,000 | +24.2% | 1,053,473 | +108.6% | 0.00% | +50.0% |
| Q4 2019 | $2,596,000 | +0.1% | 504,970 | +0.5% | 0.00% | 0.0% |
| Q3 2019 | $2,594,000 | -52.9% | 502,683 | -44.7% | 0.00% | -60.0% |
| Q2 2019 | $5,505,000 | +19.2% | 909,705 | +42.4% | 0.01% | +25.0% |
| Q1 2019 | $4,618,000 | +142.0% | 638,647 | +147.6% | 0.00% | +100.0% |
| Q4 2018 | $1,908,000 | +500.0% | 257,925 | +340.1% | 0.00% | – |
| Q3 2018 | $318,000 | +14.8% | 58,612 | -24.9% | 0.00% | – |
| Q2 2018 | $277,000 | +65.9% | 78,027 | -4.4% | 0.00% | – |
| Q1 2018 | $167,000 | -12.6% | 81,645 | +12.1% | 0.00% | – |
| Q4 2017 | $191,000 | -66.6% | 72,854 | -33.2% | 0.00% | -100.0% |
| Q3 2017 | $572,000 | +193.3% | 109,117 | +99.4% | 0.00% | – |
| Q2 2017 | $195,000 | -41.8% | 54,715 | -15.7% | 0.00% | – |
| Q1 2017 | $335,000 | +2.4% | 64,893 | -24.6% | 0.00% | – |
| Q4 2016 | $327,000 | -69.9% | 86,122 | -28.9% | 0.00% | -100.0% |
| Q3 2016 | $1,086,000 | +59.7% | 121,112 | +25.2% | 0.00% | 0.0% |
| Q2 2016 | $680,000 | +15.4% | 96,704 | +39.4% | 0.00% | 0.0% |
| Q1 2016 | $589,000 | 0.0% | 69,396 | +54.9% | 0.00% | 0.0% |
| Q4 2015 | $589,000 | +309.0% | 44,808 | +14.7% | 0.00% | – |
| Q3 2015 | $144,000 | -83.9% | 39,078 | -74.9% | 0.00% | -100.0% |
| Q2 2015 | $897,000 | +118.2% | 155,697 | +121.0% | 0.00% | – |
| Q1 2015 | $411,000 | -60.5% | 70,465 | -46.9% | 0.00% | -100.0% |
| Q4 2014 | $1,040,000 | +352.2% | 132,612 | +182.9% | 0.00% | – |
| Q3 2014 | $230,000 | -65.9% | 46,875 | -57.0% | 0.00% | -100.0% |
| Q2 2014 | $674,000 | -21.7% | 109,041 | -32.2% | 0.00% | 0.0% |
| Q1 2014 | $861,000 | +122.5% | 160,925 | +117.4% | 0.00% | – |
| Q4 2013 | $387,000 | -53.9% | 74,011 | -51.3% | 0.00% | -100.0% |
| Q3 2013 | $840,000 | +670.6% | 152,113 | +255.7% | 0.00% | – |
| Q2 2013 | $109,000 | -37.4% | 42,767 | -38.6% | 0.00% | – |
| Q1 2013 | $174,000 | – | 69,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |